Results for this period
Full year1 April 2025–31 March 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
The semiconductor-related business reported lower sales and earnings due to the impact of an adjustment phase following the exceptionally strong demand through the previous fiscal year. The measurement and weighing instruments business reported higher sales and earnings, driven by demand for measurement instruments in Japan, large-scale DSP equipment projects, profitability improvement measures, and demand in China and India. The medical and healthcare equipment business reported higher sales due to overseas demand and foreign exchange effects, while profit declined because of higher costs associated with tariffs and strengthened sales activities. Overall operating income absorbed the higher costs resulting from U.S. tariffs through appropriate pricing and productivity improvements.
Not applicable.
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | ¥69,326 million (YoY +3.3%) |
| Operating profit | ¥9,209 million (YoY +4.5%) |
| Ordinary income | ¥9,470 million (YoY +5.8%) |
| Profit attributable to owners of the parent | ¥5,923 million (YoY -8.4%) |
| Net income per share | ¥216.33 |
| Operating Margin | 13.3％ |
| Equity ratio | End of the current fiscal period 65.7％ / End of previous period 61.9％ |
| Total assets | ¥75,277 million |
| Net assets | ¥49,577 million |
| Cash flows from operating activities | ¥6,469 million |
| Cash flows from investing activities | ¥-3,792 million |
| Cash flows from financing activities | ¥-2,909 million |
| Cash and cash equivalents at end of period | ¥13,618 million |
| Full-year earnings forecast | Net Sales ¥68,000 million (YoY -1.9%) / Operating profit ¥7,000 million (YoY -24.0%) / Ordinary income ¥6,900 million (YoY -27.1%) / Net income ¥4,500 million (YoY -24.0%) |
| Annual Dividend Forecast | ¥55 → ¥60（+9.1%） |
| Payout ratio | Fiscal year ending March 2026 25.4 / Forecast for the fiscal year ending March 2027 36.5 |
| Segment revenue | Semiconductor-Related Business ¥11,114 million (YoY -9.6%), Measurement and weighing instruments business ¥31,545 million (YoY +2.9%), Medical and healthcare equipment business ¥26,667 million (YoY +10.5%) |
| Segment profit | Semiconductor-Related Business ¥3,628 million (YoY -12.0%), Measurement and weighing instruments business ¥3,387 million (YoY +25.2%), Medical and healthcare equipment business ¥4,009 million (YoY -2.4%) |
| Regional sales | Segment Semiconductor-Related Business / Regional breakdown Japan ¥11,099 million / Americas ¥0 million / Europe ¥0 million / Asia and Oceania ¥15 million, Segment Measurement and weighing instruments business / Regional breakdown Japan ¥20,241 million / Americas ¥4,989 million / Europe ¥618 million / Asia and Oceania ¥5,696 million, Segment Medical and healthcare equipment business / Regional breakdown Japan ¥4,348 million / Americas ¥11,129 million / Europe ¥10,598 million / Asia and Oceania ¥590 million |
| Depreciation and amortization | ¥1,906 million |
| Impairment loss | None recognized in the current fiscal year (—) |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥6 million / Extraordinary loss Provision for losses related to the Measurement Act ¥552 million, Loss due to embezzlement ¥243 million, Loss on sale of fixed assets ¥0 million, Loss on Disposal of Fixed Assets ¥9 million, Impairment Loss on Investment Securities ¥0 million |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 0 / Company name Not disclosed / Excluded Number of companies 1 / Company name A&D Technology Inc. / Details A&D ENGINEERING, INC. absorbed A&D Technology Inc. in a merger effective 1 April 2025, with A&D ENGINEERING, INC. as the surviving company and A&D Technology Inc. as the absorbed company |
| Material subsequent events | Not applicable. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Available (for institutional investors and analysts) |
| Issued Shares at Period-End | 27,845,208 shares |
| Treasury Shares at Period-End | 457,887 shares |
| Factors Behind Changes in Business Performance | The semiconductor-related business reported lower sales and earnings due to the impact of an adjustment phase following the exceptionally strong demand through the previous fiscal year. The measurement and weighing instruments business reported higher sales and earnings, driven by demand for measurement instruments in Japan, large-scale DSP equipment projects, profitability improvement measures, and demand in China and India. The medical and healthcare equipment business reported higher sales due to overseas demand and foreign exchange effects, while profit declined because of higher costs associated with tariffs and strengthened sales activities. Overall operating income absorbed the higher costs resulting from U.S. tariffs through appropriate pricing and productivity improvements. |
Items this document does not state (3)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The semiconductor-related business reported lower sales and earnings due to demand adjustments following the exceptionally strong demand through the previous fiscal year. The measurement and weighing instruments business reported higher sales and earnings, reflecting demand in Japan and measures to improve the profitability of DSP equipment. The medical and healthcare equipment business reported higher sales due to overseas demand and foreign exchange effects, but earnings declined because of higher costs associated with tariffs and strengthened sales activities. The decline in net income attributable to owners of the parent was affected by the recognition of ¥552 million in provision for losses related to the Measurement Act and ¥243 million in embezzlement losses.